278 related articles for article (PubMed ID: 35378995)
1. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
[TBL] [Abstract][Full Text] [Related]
4. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
Mohamed A; Kruse M; Tran J
Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
6. The role of immune checkpoint inhibition in triple negative breast cancer.
Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
Expert Rev Anticancer Ther; 2023; 23(10):1095-1106. PubMed ID: 37771270
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
9. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Barroso-Sousa R; Tolaney SM
Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
[TBL] [Abstract][Full Text] [Related]
11. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Karn T; Denkert C; Weber KE; Holtrich U; Hanusch C; Sinn BV; Higgs BW; Jank P; Sinn HP; Huober J; Becker C; Blohmer JU; Marmé F; Schmitt WD; Wu S; van Mackelenbergh M; Müller V; Schem C; Stickeler E; Fasching PA; Jackisch C; Untch M; Schneeweiss A; Loibl S
Ann Oncol; 2020 Sep; 31(9):1216-1222. PubMed ID: 32461104
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
13. Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer.
Sinn BV; Loibl S; Hanusch CA; Zahm DM; Sinn HP; Untch M; Weber K; Karn T; Becker C; Marmé F; Schmitt WD; Müller V; Schem C; Treue D; Stickeler E; Klauschen F; Burchardi N; Furlanetto J; van Mackelenbergh M; Fasching PA; Schneeweiss A; Denkert C
Clin Cancer Res; 2021 May; 27(9):2584-2591. PubMed ID: 33593886
[TBL] [Abstract][Full Text] [Related]
14. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G
Cells; 2022 Jun; 11(12):. PubMed ID: 35740985
[TBL] [Abstract][Full Text] [Related]
15. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond.
Rizzo A; Ricci AD
Expert Opin Investig Drugs; 2022 Jun; 31(6):549-555. PubMed ID: 34793275
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Dixon-Douglas J; Loi S
Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]